First Quarter 2018 Financial Results to be Announced May 8, 2018

Investor Conference Call to be Scheduled for May 17, 2018 to Discuss Updated Interim Data from Tazemetostat Trials

CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that it plans to report the company’s first quarter 2018 financial results on Tuesday, May 8, 2018.

Epizyme also plans to host a conference call and webcast for investors on the morning of May 17, 2018 to discuss recent corporate updates and new tazemetostat clinical data that will be included in upcoming medical meeting abstracts. Details for this call will be provided in the company’s May 8 press release.

About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program and its next development candidate, EZM8266, is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit


Cheya Pope, Epizyme, Inc.
(617) 229-7561

Jason Fredette, Epizyme, Inc. 
(617) 500-0623